RUNX1 and ovarian carcinoma: In ovarian cancer, RUNX1 negatively regulates the expression of the miR-17-92 cluster, which leads to the upregulation of BCL2, the direct target of miR-17-92, resulting in significant inhibition of cisplatin-induced apoptosis, which may be associated with cisplatin resistance [171].